(Total Views: 640)
Posted On: 02/06/2021 7:04:58 AM
Post# of 148887
The basic similarities with a few massive blockbuster cancer drugs selling for tens of billions annually. I am NOT suggesting LL will or could replace these blockbusters, just that a striking similarity does exist.
LERONLIMAB is a monoclonal antibody that binds to the CCR5 receptor, blocking ligands and starts a cascade of innate immune response and modulation of various sorts.
KEYTRUDA is a monoclonal antibody that binds to the PD-1 receptor, blocking ligands PD‑L1 and PD‑L2, from interacting with PD-1 to help restore T-cell response and immune response
OPDIVO® (nivolumab) and YERVOY® (ipilimumab) also binds with PD-L1 receptor, blocking ligands, and starts immune response.
Safety is key, LL is wildly safe
<<KEYTRUDA can lead to death. >>
<<OPDIVO and YERVOY can lead to death. >>
LERONLIMAB is a monoclonal antibody that binds to the CCR5 receptor, blocking ligands and starts a cascade of innate immune response and modulation of various sorts.
KEYTRUDA is a monoclonal antibody that binds to the PD-1 receptor, blocking ligands PD‑L1 and PD‑L2, from interacting with PD-1 to help restore T-cell response and immune response
OPDIVO® (nivolumab) and YERVOY® (ipilimumab) also binds with PD-L1 receptor, blocking ligands, and starts immune response.
Safety is key, LL is wildly safe
<<KEYTRUDA can lead to death. >>
<<OPDIVO and YERVOY can lead to death. >>
(6)
(0)Scroll down for more posts ▼
